Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astellas' Prograf Wins FDA Okay For Heart Transplant Indication

This article was originally published in The Pink Sheet Daily

Executive Summary

Company is awaiting FDA approval of ads before launching the new indication for the immunosuppressant tacrolimus in May.

You may also be interested in...



Prograf Ads Mislead On CV, Nephrotoxicity Risk – DDMAC

Warning letter to Astellas is not the first time FDA has cited Prograf ads for downplaying risks.

Prograf Ads Mislead On CV, Nephrotoxicity Risk – DDMAC

Warning letter to Astellas is not the first time FDA has cited Prograf ads for downplaying risks.

Fujisawa Prograf Ad Fails To Sufficiently Disclose Risks, FDA Warning Letter Says

The company’s response will include a plan of action to provide appropriate risk information. Fujisawa did not submit the journal ad for agency review at the time of its dissemination.

Topics

UsernamePublicRestriction

Register

ID1132090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel